Displaying 1 - 2 of 2
| Active Ingredient | MEDROXYPROGESTERONE |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | Long-acting contraceptive. |
| Caution | Fluid retention, weight changes. |
| Dose Range | 150mg every 12 weeks for contraception. The first injection for contraception must be given ONLY during the first 5 days of a normal menstrual period, ONLY within the first 5-days postpartum if not breast feeding; and if exclusively breastfeeding |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEDROXYPROGESTERONE |
| Therapeutic Class | PROGESTINS |
| Indications |
Anovulatory dysfunctional uterin e bleeding (DUB), post menopausal hormone replacement therapy, contraception, carcinoma of the endometrium. |
| Caution | Fluid retention, menstrual disorders. Use with caution in conditions which worsen fluid retention. c.f. prescribing in liver disease p. 15. |
| Dose Range |
Oral: 2.5-10mg daily for at least 10 day s p er month as HRT; daily from day s 16 or 21 of cycle for 5-10 days in anovulatory DUB. Higher p arenteral doses are required in endometrical cancer. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |